Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for

Status Recruiting

Clinical Trial Summary

Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The investigators try to observe the efficacy and safety of application of vedolizumab, anti-CD25 monoclonal antibody and rapid reduction of glucocorticoids in the treatment of grade 3-4 steroid-refractory aGVHD(SR-aGVHD) with lower gastrointestinal involvement.

Clinical Trial Description

Sample size: According to Simon optimal two-stage design, P0=60%, P1=80%, α=0.05, β=0.2, a sample size of 45 was chosen. Objects: Adults ages 18-65 diagnosed with grade 3-4 SR-aGVHD with lower gastrointestinal involvement. Design Participants with grade 3-4 SR-aGVHD with lower gastrointestinal involvement(progression after 3 days or lack of improvement after 5 days of 1-2 mg/kg/d systemic steroids) receive combined therapy of vedolizumab and anti-CD25 monoclonal antibody, with methylprednisolone terminated in 7-10 days. Vedolizumab is given 300mg, day 1/15/43, and then once every 8 weeks until gastrointestinal GVHD reaches grade 1 (1 episodes for minimum). Basiliximab is given 20mg twice a week for week 1, and then once a week until GVHD of the participants reaches grade 2(3 episodes for minimum). If basiliximab is not available, it can be replaced by recombinant humanized anti-CD25 monoclonal antibody injection, 50mg once with the same frequency. Methylprednisolone is reduced to 1mg/kg/d at day 1 and is aborted in 7-10 days. If chronic GVHD or overlap syndrome is considered later during treatment, steroids (ie. methylprednisolone 0.5mg/kg/d) can be administered again. Intravenous cyclosporine or tacrolimus is given and plasma concentration is monitored in a safe and effective range. Best supportive treatment is given, including broad-spectrum anti-infection, nutrition support, and blood transfusion. The investigators access the efficacy and safety of second-line therapy once a week from day 14 until complete remission is received. Then the investigators access the hematological disease status, aGVHD, cGVHD, infection state once a month. ;

Study Design

Related Conditions & MeSH terms

Safety and Efficacy

Clinical Trial Details

NCT number	NCT06066840
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Xuefeng He, doctor
Phone	86-18914031640
Email	hexuefeng@suda.edu.cn
Status	Recruiting
Phase	Phase 4
Start date	August 1, 2022
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04994210` - Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL	Phase 2
Terminated	`NCT05247957` - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia	N/A
Completed	`NCT04621123` - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients	Phase 2
Recruiting	`NCT05140616` - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD	Phase 1/Phase 2
Recruiting	`NCT05349552` - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed	`NCT03820596` - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL	Phase 1/Phase 2
Not yet recruiting	`NCT05556889` - Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block	N/A
Recruiting	`NCT04446806` - Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia	Phase 4
Not yet recruiting	`NCT06244537` - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer	N/A
Recruiting	`NCT03455972` - Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	Phase 1/Phase 2
Completed	`NCT04785170` - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals	N/A
Recruiting	`NCT04677452` - Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM	Phase 1
Completed	`NCT01305044` - The HEALS Project - Health Education and Active Living for Surviving Seniors	Phase 2
Active, not recruiting	`NCT04646590` - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19	Phase 3
Recruiting	`NCT05021276` - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD	Phase 4
Not yet recruiting	`NCT05008666` - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH	Phase 2
Active, not recruiting	`NCT04852068` - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms